TATVA CHINTAN PHARMA CHEM
|
TATVA CHINTAN PHARMA CHEM Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 20.52 | 43.25 | 26.02 | 47.03 | 25.57 |
| CEPS(Rs) | 24.83 | 46.95 | 29.37 | 21.20 | 12.23 |
| DPS(Rs) | 2.00 | 2.00 | 5.00 | - | - |
| Book NAV/Share(Rs) | 232.25 | 213.44 | 82.62 | 146.48 | 99.19 |
| Tax Rate(%) | -1.58 | 7.92 | 13.90 | 20.61 | 25.01 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.34 | 25.01 | 22.20 | 21.00 | 16.54 |
| EBIT Margin(%) | 12.59 | 25.20 | 21.69 | 19.70 | 15.19 |
| Pre Tax Margin(%) | 10.57 | 24.00 | 20.21 | 18.08 | 13.28 |
| PAT Margin (%) | 10.73 | 22.10 | 17.40 | 14.36 | 9.96 |
| Cash Profit Margin (%) | 12.99 | 23.98 | 19.64 | 16.18 | 11.91 |
| Performance Ratios | |||||
| ROA(%) | 6.53 | 19.68 | 18.21 | 17.32 | 12.28 |
| ROE(%) | 9.21 | 30.01 | 36.85 | 38.29 | 28.95 |
| ROCE(%) | 8.35 | 25.75 | 28.04 | 28.40 | 22.78 |
| Asset Turnover(x) | 0.61 | 0.89 | 1.05 | 1.21 | 1.23 |
| Sales/Fixed Asset(x) | 2.03 | 2.67 | 2.30 | 2.69 | 2.88 |
| Working Capital/Sales(x) | 5.47 | 1.64 | 4.53 | 5.84 | 4.94 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.49 | 0.37 | 0.44 | 0.37 | 0.35 |
| Receivable days | 60.72 | 61.98 | 85.26 | 62.97 | 64.50 |
| Inventory Days | 143.16 | 101.78 | 82.38 | 68.74 | 57.57 |
| Payable days | 61.91 | 86.25 | 94.96 | 73.88 | 74.80 |
| Valuation Parameters | |||||
| PER(x) | 81.23 | 53.35 | - | - | - |
| PCE(x) | 67.12 | 49.16 | - | - | - |
| Price/Book(x) | 7.18 | 10.81 | - | - | - |
| Yield(%) | 0.12 | 0.09 | - | - | - |
| EV/Net Sales(x) | 9.02 | 11.66 | 0.35 | 0.33 | 0.34 |
| EV/Core EBITDA(x) | 57.43 | 43.03 | 1.46 | 1.55 | 2.01 |
| EV/EBIT(x) | 71.57 | 46.25 | 1.61 | 1.69 | 2.22 |
| EV/CE(x) | 5.14 | 7.79 | 0.32 | 0.35 | 0.37 |
| M Cap / Sales | 8.72 | 11.80 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -2.31 | 44.38 | 14.10 | 27.60 | 52.30 |
| Core EBITDA Growth(%) | -43.40 | 63.52 | 26.86 | 63.71 | 31.72 |
| EBIT Growth(%) | -51.19 | 67.87 | 25.60 | 65.49 | 38.26 |
| PAT Growth(%) | -52.56 | 83.45 | 38.30 | 83.95 | 58.03 |
| EPS Growth(%) | -52.56 | 66.26 | -44.68 | 83.95 | 58.03 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.33 | 0.25 | 0.54 | 0.77 | 0.97 |
| Current Ratio(x) | 1.33 | 2.54 | 1.52 | 1.51 | 1.57 |
| Quick Ratio(x) | 0.64 | 1.55 | 0.95 | 0.79 | 1.08 |
| Interest Cover(x) | 6.21 | 20.90 | 14.65 | 12.15 | 7.94 |
| Total Debt/Mcap(x) | 0.05 | 0.02 | - | - | - |
Compare Financial Ratios of peers of TATVA CHINTAN PHARMA CHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TATVA CHINTAN PHARMA CHEM | ₹2,902.2 Cr | 2.2% | 6.9% | -23.5% | Stock Analytics | |
| PIDILITE INDUSTRIES | ₹151,652.0 Cr | 3.2% | 0.6% | 21% | Stock Analytics | |
| SOLAR INDUSTRIES INDIA | ₹79,493.7 Cr | 3.2% | -1.3% | 129.8% | Stock Analytics | |
| SRF | ₹78,183.5 Cr | 4.4% | 4% | 5.7% | Stock Analytics | |
| GUJARAT FLUOROCHEMICALS | ₹40,128.2 Cr | 1.6% | 17.8% | 10.7% | Stock Analytics | |
| DEEPAK NITRITE | ₹33,801.6 Cr | 6.7% | 12.8% | 30.5% | Stock Analytics | |
TATVA CHINTAN PHARMA CHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TATVA CHINTAN PHARMA CHEM | 2.2% |
6.9% |
-23.5% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
